Ajanta Pharma Q2FY26 Earnings Results Out: Company Declares ₹28 Interim Dividend

As per Ajanta Pharma Q2FY26 earnings results, the company’s branded generics business has outperformed the Indian Pharmaceutical Market (IPM). Driven by robust growth in ophthalmology and dermatology, its business has exceeded industry growth by 32%. 

How Does the Ajanta Pharma Q2FY26 Earnings Results Fare Against Q2FY25?

Segment-Wise Breakdown of Ajanta Pharma Q2FY26 Earnings Results 

For the quarter ended September 30, 2025, Ajanta Pharma reported a 20% rise in consolidated net profit and a 14% increase in revenue. 

Ajanta Pharma Declares ₹28 Dividend 

Ajanta Pharma’s Board of Directors approved the first interim dividend for FY26 at ₹28 per equity share of ₹2 each. The total dividend payout amounts to ₹349.82 crore.

The company fixed November 10, 2025, as the record date, and the dividend will be paid on or after November 20, 2025. Investors with a demat account must hold the shares of Ajanta Pharma as of November 10, 2025, to be eligible for this dividend. This dividend reflects the company’s commitment to rewarding its shareholders while maintaining a strong balance sheet. 

Read more: Dividends and Bonus Issue This Week (November 3-7, 2025): Lal PathLabs, Mazagon Dock, and More.

Conclusion

Ajanta Pharma’s Q2FY26 results reflect a period of solid growth supported by its strong product portfolio, consistent expansion in key markets, and efficient operations. With a healthy dividend and rising contributions from both domestic and international businesses, the company remains well-positioned for continued growth in the coming quarters. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.